Study: FDG-PET affects recurrent glioma treatment management

06/24/2008 | AuntMinnie.com (free registration)

Researchers in Australia used data from the Australian PET Data Collection Project and found that the treatment plans for 45% of suspected recurrent glioma patients were affected by FDG-PET results. "The aim of this project is to present data in gliomas and assist in the impact of FDG-PET on the management of patients with a residual structural lesion after prior treatment for glioma and then determine incremental information provided by PET in that context," said one of the researchers.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN